MAVALON THERAPEUTICS
Mavalon Therapeutics is a company focused on stopping the progression of Parkinson’s disease. The biotechnology company is developing mGluR3 allosteric modulators for the treatment of Parkinson's disease.
MAVALON THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2016-01-01
Address:
Hatfield, Hertford, United Kingdom
Country:
United Kingdom
Total Employee:
1+
Status:
Active
Total Funding:
9 M EUR
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Vincere Biosciences
Vincere Biosciences is a JLABS incubator company whose mission is to develop drugs to halt the progression of Parkinson's disease (PD).
Investors List
Domain Therapeutics
Domain Therapeutics investment in Seed Round - Mavalon Therapeutics
Medicxi
Medicxi investment in Seed Round - Mavalon Therapeutics
More informations about "Mavalon Therapeutics"
Domain Therapeutics and Medicxi launch Mavalon Therapeutics, …
Strasbourg, France, October 18, 2016 – Domain Therapeutics, a biopharmaceutical company that specializes in the discovery and development of G protein-coupled receptor (GPCR) drugs, …See details»
Mavalon Therapeutics 2025 Company Profile: Valuation, Funding ...
Mavalon Therapeutics General Information Description. Developer of an oral drug intended to treat Parkinson's disease (PD). The company's drugs halt the progression of the disease and …See details»
Canada’s Domain Therapeutics creates new company to stop …
Oct 20, 2016 An mGluR4 PAM is ready to enter Phase II at Prexton Therapeutics, while a dual adenosine A2A/A1 receptor antagonist is in preclinical development at Kaldi Pharma. Both …See details»
Domain Therapeutics 161018 Mavalon EN
Domain Therapeutics Strasbourg, France, October 18, 2016 – Domain Therapeutics, a biopharmaceutical company that specializes in the discovery and development of G protein …See details»
Mavalon Therapeutics - Funding, Financials, Valuation & Investors
Mavalon Therapeutics is funded by 2 investors. Domain Therapeutics and Medicxi are the most recent investors. Which investors participated in the most funding rounds?See details»
Mavalon Therapeutics
Mavalon Therapeutics. A biotechnology company developing mGluR3 allosteric modulators for the treatment of Parkinson's disease. CEO. Domain Therapeutics. HQ. Cambridge, UK. Team …See details»
Mavalon Therapeutics - VentureRadar
A biotechnology company developing mGluR3 allosteric modulators for the treatment of Parkinson's disease. ... Find out more about Mavalon Therapeutics, Small Molecule …See details»
Mavalon Therapeutics Ltd - Company Profile and News
Company profile page for Mavalon Therapeutics Ltd including stock price, company news, executives, board members, and contact informationSee details»
Mavalon Therapeutics - Crunchbase
Mavalon is developing drugs to stop the progression of Parkinson's disease.See details»
This New Biotech wants to Regrow Neurons to cure …
Oct 18, 2016 Mavalon Therapeutics will develop a drug candidate for Parkinson's that can stop the disease progression by activating the growth of dying neurons. Skip to content. Search for: Suggested Topics: Categories . …See details»
Mavalon Therapeutics - 2025 Company Profile - Tracxn
Feb 23, 2025 Mavalon Therapeutics - Developing novel small molecule therapeutics to treat Parkinson's Disease. This company is not active anymore. Mavalon Therapeutics has 536 …See details»
Domain Therapeutics And Medicxi Launch Mavalon Therapeutics …
Oct 18, 2016 An mGluR4 PAM is ready to enter Phase II at Prexton Therapeutics and a dual adenosine A2A/A1 receptor antagonist is in preclinical development at Kaldi Pharma. Both …See details»
Domain Therapeutics and Medicxi launch Mavalon Therapeutics
Strasbourg, France, October 18, 2016 – Domain Therapeutics, a biopharmaceutical company that specializes in the discovery and development of G protein-coupled receptor (GPCR) drugs, …See details»
Mavalon Therapeutics - Products, Competitors, Financials, …
Domain Therapeutics and Medicxi launch Mavalon Therapeutics, Aimed at Halting the Progression of Parkinson’s Disease 04:26 EST 7 Nov 2016 | Lab Bulletin Home » Topics » …See details»
Medicxi founds Parkinson’s startup, commits €9M
Oct 18, 2016 Mavalon Therapeutics, the asset-centric company founded to advance the candidate, will receive up to €9 million ($10 million) from Medicxi. As with other Medicxi …See details»
MAVALON THERAPEUTICS LIMITED - Companies House
Insolvency for MAVALON THERAPEUTICS LIMITED (10017462) More for MAVALON THERAPEUTICS LIMITED (10017462) Registered office address Montague Place Quayside, …See details»
Mavalon Therapeutics - Updates, News, Events, Signals & Triggers
Mavalon is developing drugs to stop the progression of Parkinson's disease.See details»
Safety and Efficacy of Mavacamten and Aficamten in Patients With ...
Mar 8, 2025 Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease in the world, which if left untreated carries significant morbidity. 1 Conventional pharmacological …See details»
Domain Therapeutics and Medicxi launch Mavalon Therapeutics, …
Strasbourg, France, October 18, 2016 – Domain Therapeutics, a biopharmaceutical company that specializes in the discovery and development of G protein-coupled receptor (GPCR) drugs, …See details»
Mavalon Therapeutics - Tech Stack, Apps, Patents & Trademarks
Mavalon is developing drugs to stop the progression of Parkinson's disease.See details»